Clinical trials: Withdrawal Syndrome
Tobacco Dependence, Withdrawal Symptoms
Varenicline OTC Trial on Efficacy and Safety
The primary goal of the proposed research is to test whether varenicline (Chantix) is safe and effective as an over-the-counter (OTC) medication.
- Conditions
- Tobacco Dependence, Withdrawal Symptoms, Smoking Cessation
- Trial name
- VOTC (NCT03557294)
- Testing
- 1.0mg Varenicline b.i.d., 0.5mg Varenicline b.i.d.
- Where
- 2 sites in United States
- Volunteers
- 313 people, healthy volunteers welcome
- Sponsor
- Arizona State University
Substance Withdrawal Syndrome
Effect of Ondansetron for Withdrawal Symptoms
We hope to determine whether Ondansetron, an anti-nausea medication, works to help relieve withdrawal symptoms experienced while the patient is being weaned off opioid medications.
- Trial name
- NCT00695864
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Stanford University
Alagille Syndrome
Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)
This is a long-term, open-label study with a double-blind, placebo-controlled, randomized drug withdrawal period in children with Alagille Syndrome (ALGS) designed to evaluate the safety and efficacy of LUM001 (Also known as…
- Trial name
- ICONIC (NCT02160782)
- Testing
- LUM001 (Maralixibat)
- Where
- 9 sites in Australia, Belgium and 4 more
- Volunteers
- 31 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal
Improving Outcomes in Neonatal Abstinence Syndrome
1: SPECIFIC Aim I: To compare treatment options for neonatal abstinence syndrome (NAS) due to in-utero narcotic exposure. One hundred eighty four full-term infants with a diagnosis of NAS requiring medications will be studied.
- Trial name
- NCT01958476
- Testing
- Neonatal Morphine Solution, Methadone, Phenobarbital
- Where
- 8 sites in United States
- Volunteers
- 117 people
- Sponsor
- Tufts Medical Center
Drug Withdrawal Headache
Postoperative Headache in Elective Surgery Patients
To evaluate the association of anaesthesia and surgery with postoperative headache in elective surgery patients By multiple logistic regression analysis of data collected during a six-month period from 446 patients undergoing…
- Trial name
- NCT02374346
- Volunteers
- 494 people
- Sponsor
- Attikon Hospital
Lambert-Eaton Myasthenic Syndrome, Eaton-Lambert Myasthenic Syndrome
Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
Hypothesis: 3,4-Diaminopyridine base (3,4-DAP) improves Lambert-Eaton Myasthenic Syndrome (LEMS)-related weakness.
- Trial name
- DAPPER (NCT01511978)
- Testing
- Continuous 3,4-DAP
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Jacobus Pharmaceutical
Irritable Bowel Syndrome Characterized by Constipation
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
To evaluate the efficacy on abdominal symptoms (abdominal bloating, abdominal discomfort, and abdominal pain) and safety of linaclotide 290 μg administered orally to patients with IBS-C.
- Trial name
- NCT03573908
- Testing
- Linaclotide
- Where
- 79 sites in United States
- Volunteers
- 614 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Substance Withdrawal Syndrome
Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED
Withdrawal from opioids is a clinical scenario that emergency department physicians encounter frequently. Patients who present with opioid withdrawal display symptoms such as agitation, anxiety, myalgias, abdominal pain…
- Trial name
- NCT02643355
- Testing
- Olanzapine, Clonidine
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hennepin Healthcare Research Institute
Enteropathy, Celiac Disease
Budesonide in Patients With Immune Mediated Enteropathies
Researchers are trying to determine if withdrawal of budesonide therapy in patients with immune-mediated enteropathies doing well on therapy will result in worsening symptoms, histology, quality of life, and…
- Conditions
- Enteropathy, Celiac Disease, CVID Enteropathy, Collagenous Sprue
- Trial name
- NCT03866538
- Testing
- Withdrawal of Oral Budesonide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria
Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Inflammatory symptoms of Cryopyrin-Associated Periodic Syndrome (CAPS) are due to mutations in a the NLRP-3 gene (previously known as Cold Induced Autoinflammatory Syndrome-1 or CIAS1).
- Conditions
- Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria, Muckle-Wells Syndrome (MWS), Genetic Diseases, Inborn
- Trial name
- NCT00288704
- Testing
- rilonacept 160 mg
- Where
- 24 sites in United States
- Volunteers
- 104 people
- Sponsor
- Regeneron Pharmaceuticals
Neonatal Abstinence Syndrome
tAN to Mitigate Withdrawal Behaviors in Neonates
This first in-human-neonates, open-label pilot trial is designed to determine whether use of tAN in newborns with NOWS receiving oral morphine allows for faster weaning of morphine and decrease morphine use altogether.
- Trial name
- NCT04588519
- Testing
- Spark Biomedical Roo Transcutaneous Auricular Neurostimulation (tAN) System
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Spark Biomedical, Inc.
Neonatal Opiate Withdrawal Syndrome
Optimizing Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome (OPTimize NOW): A Symptom-Based Dosing Approach
This clinical trial will help us learn more about how to best care for babies with Neonatal Opioid Withdrawal Syndrome, also called NOWS.
- Trial name
- OPTimize NOW (NCT05980260)
- Testing
- Symptom-based Dosing Approach, Scheduled Opioid Taper Approach
- Where
- 23 sites in United States
- Volunteers
- 626 people
- Sponsor
- HELP for NOWS Consortium
Substance Withdrawal Syndrome
Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal
Prescription opioid addiction is a growing public health problem and more pharmacologic treatments are needed because current approved medications have had limited patient acceptance (naltrexone), limited availability…
- Trial name
- NCT00980044
- Testing
- Tramadol
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Michelle Lofwall
Opioid Use, Unspecified With Withdrawal, Opioid-Induced Disorders
Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit
The purpose of this study is to determine if administering methadone to mechanically ventilated patients in the medical intensive care unit (ICU) requiring continuous infusions of sedatives and analgesics will decrease the time…
- Conditions
- Opioid Use, Unspecified With Withdrawal, Opioid-Induced Disorders, Delirium
- Trial name
- NCT02025855
- Testing
- Methadone
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Henry Ford Health System
Muckle Wells Syndrome
Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome
This study is designed to provide efficacy and safety data for ACZ885 (a fully human anti-interleukin-1beta (anti-IL-1beta) monoclonal antibody) administered as an injection subcutaneously (s.c.) in patients with Muckle-Wells…
- Trial name
- REMITTER (NCT00465985)
- Testing
- ACZ885
- Where
- 12 sites in United States, France and 4 more
- Volunteers
- 35 people
- Sponsor
- Novartis
Delirium, Psychomotor Agitation
Nicotine Replacement Therapy in the Intensive Care Unit
The purpose of this study is to determine whether transdermal nicotine replacement therapy is safe and effective for treating nicotine withdrawal symptoms in the critically ill smoking patient.
- Conditions
- Delirium, Psychomotor Agitation, Substance Withdrawal Syndrome, Nicotine Replacement Therapy
- Trial name
- NicGoWell (NCT01362959)
- Testing
- Transdermal nicotine patch, Cutaneous patch, containing no active substances
- Where
- 2 sites in Netherlands
- Volunteers
- 47 people
- Sponsor
- Gelderse Vallei Hospital
Neonatal Abstinence Syndrome
Comparison Between Methadone and Morphine for Neonatal Opiate Withdrawal
Hypothesis is that the effectiveness of opiate treatment with morphine will result in shorter duration of opiate medication treatment and fewer infants treated with a second drug.
- Trial name
- NAS (NCT01804075)
- Testing
- Methadone, Morphine
- Volunteers
- 31 people
- Sponsor
- Eastern Maine Medical Center
Irritable Bowel Syndrome Characterized by Constipation
Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation
The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with irritable bowel syndrome with constipation (IBS-C).
- Trial name
- NCT00948818
- Testing
- Linaclotide 290 micrograms
- Where
- 118 sites in United States, Canada
- Volunteers
- 803 people
- Sponsor
- Forest Laboratories
Neonatal Opiate Withdrawal Syndrome
Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach
The overall objective is to determine if the ESC care approach will reduce the time until infants being managed for NOWS are medically ready for discharge.
- Trial name
- (ESC-NOW) (NCT04057820)
- Testing
- Finnegan Neonatal Abstinence Scoring Tool, Eat, Sleep, Console (ESC) care tool
- Where
- 26 sites in United States
- Volunteers
- 1,305 people
- Sponsor
- Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program
Exocrine Pancreatic Insufficiency, Steatorrhea
A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency
The purpose of this study is to assess the effectiveness and safety of oral pancrelipase MT in the treatment of adult and pediatric/adolescent cystic fibrosis (CF) patients with clinical symptoms of exocrine pancreatic…
- Conditions
- Exocrine Pancreatic Insufficiency, Steatorrhea, Malabsorption Syndromes, Cystic Fibrosis
- Trial name
- NCT00662675
- Testing
- Pancrease MT 10.5, or MT 21
- Where
- 11 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.